Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068249 · ClinicalTrials.gov registry record · Phase 2
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT01068249 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01068249, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG RAD001 (Everolimus)
Study Locations (2)
New Jersey
- Morristown Memorial Hospital, Women's Cancer Center - Morristown
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-04-30 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068249
The ClinicalTrials.gov registry entry for NCT01068249 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Letrozole is the first listed.
NCT01068249 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT01068249 about?
NCT01068249 is a clinical study titled "Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer". The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT01068249?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2010-04-30. Estimated completion is 2028-04-30.
What conditions does trial NCT01068249 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT01068249?
The interventions under investigation include: Letrozole (DRUG), RAD001 (Everolimus) (DRUG).
Who is sponsoring clinical trial NCT01068249?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01068249 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.